Introduction: Pancreatic cancer is one of the top ten causes of cancer related deaths world-wide. The only treatment offering an advantage in terms of overall survival is radical complete resection of pancreatic carcinoma. But, only 10-20% present with resectable disease at the time of diagnosis. Single agent gemcitabine still remains the standard therapy for advanced/ metastatic pancreatic cancer after indecisive conclusions with combination therapy of oxiplatin and gemicitabine. Nab-paclitaxel (albumin bound paclitaxel) has demonstrated a better overall survival in phase III trials in combination with gemcitabine. Case Report: The two cases mentioned below are cases of advanced pancreatic cancer which have demonstrated an affirmative response to combination therapy of nab-paclitaxel and gemcitabine in first line and beyond. Conclusion: Gemcitabine, although the standard of care in the treatment of advanced pancreatic cancer, shows better efficacy and survival when used in combination with nab-paclitaxel.